Pharmaceutical Executive-02-01-2018

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders-most importantly, patients and the wider public.

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.

Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.

Low-cost follow-ons and biosimilars please payers but heighten competitive battles with brands.

Assembling a few rare slivers of pharma positivity on UK’s future.

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders-call it the quest to see "what right looks like?"

2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead?

In its ambition to further strengthen the nation’s relationship with the global industry, Brazil holds a valuable, eye-catching asset: the dynamism of its huge pharmaceutical market, the sixth-largest in the world.

Click the title above to open the Pharmaceutical Executive February 2018 issue in an interactive PDF format.